Stock market Updates | Natco Pharma Ltd. | R Wadiwala Securities Pvt Ltd
investments Associate Login Online Trading Login

We are investment service provider for Buy stocks , Low Stocks Brokerage , Stocks Portfolio Management in Surat , NRI Investment in Stocks , Share Broking Surat , Stock Broking Surat , Advisory Services Surat and Competetive Stocks Brokerage. investment advisory, financial integrity and prompt services in the whole of South Gujarat.

equity
Home Markets & NewsCompany ProfileSmart Quotes

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE980.5536.1 (+3.82 %)
PREV CLOSE (Rs.) 944.45
OPEN PRICE (Rs.) 949.95
BID PRICE (QTY) 979.00 (20)
OFFER PRICE (QTY) 979.80 (5)
VOLUME 165362
TODAY'S LOW / HIGH (Rs.)942.85 990.45
52 WK LOW / HIGH (Rs.)660.05 1059.6
NSE989.6044.75 (+4.74 %)
PREV CLOSE( Rs. ) 944.85
OPEN PRICE (Rs.) 948.00
BID PRICE (QTY) 989.50 (6)
OFFER PRICE (QTY) 989.85 (153)
VOLUME 1921861
TODAY'S LOW / HIGH(Rs.) 942.95 990.00
52 WK LOW / HIGH (Rs.)726.8 1059

Smart Quotes

BSE NSE
1D 1M 3M 1Y 3Y 5Y
Stock Summary
Trade Value (Rs. in Lacs)
1621.46
Dividend Yield(%)
0.64
TTM EPS (Rs.)
83.75
P/E Ratio
11.28
Book Value (Rs.)
467.76
Face Value (Rs.)
2
MCap (Rs. in Mn)
169160.32
Price/Earning (TTM)
9.73
Price/Sales (TTM)
4.08
Price/Book (MRQ)
2.02
PAT Margin (%)
43.69
ROCE (%)
33.11
company info
Incorporation Year : 19-09 1981

Management Info :

V C Nannapaneni - Chairman V C Nannapaneni - Managing Director

Registered Office :

Address : Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040-23547532

Registrars Details :

Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE, NSE
News
16Feb Natco Pharma jumps on getting CDSCO’
Natco Pharma is currently trading at Rs. 885.35, up by 63.25 points or 7..
14Feb Natco Pharma gets CDSCO’s approval f
Natco Pharma has received approval from Central Drugs Standard Control O..
13Feb Natco Pharma gets EIR for API division
Natco Pharma has received Establishment Inspection Report (EIR) from U.S..
more
Financials
QTR Dec 25 ANNUAL 25
Net Profit106918504
Gross Profit 1252 22260
Operating Profit 1756 24656
Net Sales 5288 40945
more
Rs. in Millions
Rolling Forward P/E (EOD)
Event Calendar
peer group
Kwality Pharma (BSE)
Rwadiwala-peer-arrow  1418.00 (5.88%)
M.Cap (Rs. in Cr)1389.68
Mercury Laboratories (BSE)
Rwadiwala-peer-arrow  867.00 (8.17%)
M.Cap (Rs. in Cr)96.19
Pfizer (BSE)
Rwadiwala-peer-arrow  5127.00 (0.80%)
M.Cap (Rs. in Cr)23269.81
Sanofi Cons. Health (BSE)
Rwadiwala-peer-arrow  4036.00 (0.92%)
M.Cap (Rs. in Cr)9210.64
Shareholding Pattern
PROMOTERS
49.48%
FI/BANKS/INSURANCE
3.5%
NON-INSTITUTION
29.97%
MUTUAL FUNDS/UTI
1.6%
GOVERNMENT
0%
FII
0%
more
Mf Holdings
ATTENTION INVESTORS|KYC|IPO|PROPRIETARY TRADING
Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors.    
ATTENTION INVESTORS Advisory for Investors Advisory - KYC Compliance
  • 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
  • 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • 3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors
CORPORATE OFFICE
address
  • 9/2003-4,
  • Vishnu Priya Limda Chowk
  • Main Road
  • Surat – 395 003.
fax us @ +91-261-6673537
email us @ emailimg

Feed Back  | Terms & Conditions  | SEBI  | FMC  | NSE  | BSE  |  Advisory For Investors  |  MCX  | IRDA  |  AMFI  | Disclaimer  | Privacy Policy  | Careers | User Agreements  | Ethics Policy  | Investor Protection  |  Dos and Don'ts   |  Rights and Obligations   |  Uniform Risk Disclosure   |   Important Policies   |  Investor Charter   |  Investor Complaints   | To File A Complaint on SCORES   |   Online Dispute Resolution Portal (ODR Portal) |   CLIENT BANK ACCOUNT DETAILS  |   BSE Client-wise Collateral  |   NSE Client-wise Collateral |  INVESTOR GRIEVANCE REDRESSAL MECHANISM |   SOP of Centralized Mechanism for reporting the demise of an investor through KRAs |  Sitemap 

BSE, NSE, MCX SEBI Regn no.: INZ000187332 | PMS SEBI Regn no.: INP000004045 | CDSL SEBI Regn No.: IN-DP-112-2015 | CDSL DP ID: 12043100
| R Wadiwala Securities Pvt Ltd - CIN: U67120GJ2004PTC044324

Compliance Officer - Email ID: compliance@rwadiwala.com | Contact No.: 0261-6673542

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by us, our employees, and our servants.

Investor Greivance Redressal at support@rwadiwala.com

Copyright © 2016 | All Rights Reserved. R.Wadiwala group.

Designed & Developed by ●●● Accord Fintech Pvt. Ltd.